Falkson H C, Falkson G, Portugal M A, Schoeman H S, Louw E M
S Afr Med J. 1982 May 1;61(18):651-5.
Surgery alone does not cure breast cancer, and adjuvant chemotherapy has changed the management of this disease. Data obtained in 81 premenopausal women with operable breast cancer, treated at our clinic, are presented. Patients with axillary node disease were treated on three different protocols: cyclophosphamide + methotrexate + fluoro-uracil + vincristine + prednisone (CMFVP), cyclophosphamide + methotrexate + fluoro-uracil (CMF), and CMF + immunotherapy with methanol extract residue of BCG (CMF + MER). Patient discriminants and treatment regimens are discussed. Analysis of the results obtained in 49 patients in one study showed an extension of disease-free survival to 4,25 years, that CMFVP was superior to CMF with or without MER, and that immunotherapy was not beneficial. The literature is briefly reviewed and the motivation for our newer studies stated.
单纯手术无法治愈乳腺癌，辅助化疗改变了这种疾病的治疗方式。本文展示了在我们诊所接受治疗的81例绝经前可手术乳腺癌女性患者的数据。有腋窝淋巴结疾病的患者采用三种不同方案进行治疗：环磷酰胺+甲氨蝶呤+氟尿嘧啶+长春新碱+泼尼松（CMFVP）、环磷酰胺+甲氨蝶呤+氟尿嘧啶（CMF）以及CMF+卡介苗甲醇提取物残渣免疫疗法（CMF+MER）。讨论了患者判别因素和治疗方案。一项研究中对49例患者的结果分析显示，无病生存期延长至4.25年，CMFVP优于CMF（无论有无MER），且免疫疗法并无益处。本文简要回顾了相关文献，并阐述了我们开展最新研究的动机。
